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Abstract
Traditionally the treatment for hematologic malignancy, including adults 
(>18 years old) has been a bone marrow transplant using either a 
matched related donor, such as a sibling, or matched unrelated donor 
using HLA typing. Only 30% of patients have a family member eligible 
to donate their bone marrow with the remaining 70% of patients left to 
find an HLA match through the registry¹.Haploidentical bone marrow 
transplants would provide a treatment option for numerous patients that 
have children or parents eligible to donate their bone marrow.
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Introduction
Methods
A literature search was conducted through PubMed and EBSCO in 
November 2019. Seven articles were selected based on their relevance to 
the research topic, study design, measurements, and results.
● Inclusion criteria: allogeneic bone marrow transplant, adult, humans, 
haploidentical,  published in last 6 years.
● Exclusion criteria: relapse after second transplant, meta-analysis, 
animal models, umbilical cord, sickle cell anemia
As seen in Table 1, 6 out of 7 of the studies found statistically significant 
differences between incidences of cGVHD, aGVHD, and OS with 
overall lower incidences in patients that received transplantation from 
haploidentical donors. One study by Wang Y et al. found aGVHD and 
cGVHD to be slightly higher in patients receiving transplantation from 
haploidentical donors. This was the only study with this finding, all other 
studies found overall lower incidences of aGVHD and cGVHD.  In 
terms of validity, as seen in Appendix B, all studies did not demonstrate 
any bias and followed standardized criteria for the definition of aGVHD, 
cGVHD, and OS. The statistical power of all studies was deemed 
adequate except for the study by Sun Y et al. which had the lowest 
sample size at only 87. External validity was also unclear because bone 
marrow transplantation itself is a complex procedure where pre-existing 
health status and comorbidities can greatly impact the success of the 
transplant itself. These studies were unable to control for all of the 
variables that may exist in the patients themselves prior to 
transplantation such as presence or absence of hypertension, 
hyperlipidemia, diabetes, etc. Additionally, limitations across all studies 
include variation in preconditioning used prior to transplantation of 
donor stem cell and GVHD regimen following transplantation. These 
must be controlled for and then compared against one another to ensure 
that it is the difference in donor and not any difference in 
preconditioning regimen or post transplant GVHD prophylaxis that is 
causing the change in aGVHD, cGVHD, or overall survival.
Discussion 
Table 1. Comparison of Results 
Key: aGVHD= acute graft versus host disease, cGVHD= 
chronic graft versus host disease, OS= overall survival, S= 
Significant, NS= Not Significant
Results 
If further research does continue to demonstrate that haploidentical bone 
marrow transplantation is at least comparable if not even better than 
matched donor transplantation, the implications would extend as far as 
decreasing racial difference in transplantation among ethnic minorities.  
Overall, while there certainly is hope for the future of bone marrow 
transplantation, further research must be conducted prior to making large 
changes in protocol.
Conclusion
Based on the literature review, there is hopeful evidence that 
bone marrow transplantation from haploidentical donors 
may have lower incidences of adverse outcomes such as 
acute GVHD and chronic GVHD, as demonstrated by 6 out 
of the 7 studies analyzed in this paper. Only one study 
analyzed out of the 7 studies found patients receiving bone 
marrow transplantation from haploidentical donors to have 
higher incidences of acute GVHD and chronic GVHD. The 
cumulative incidence of grade II-IV acute GVHD was 49% 
in the haploidentical donor transplantation group and 24% in 
the identical sibling donor transplantation group. The 
cumulative incidence of grades III-IV was 15% in the 
haploidentical donor transplantation group and 4% in the 
identical sibling donor transplantation group. (Wang et al, 
2011). In all of the other 6 studies, both acute GVHD and 
chronic GVHD incidences were found to be equal or lower 
when haploidentical donor matches were used for treatment.
Bone marrow transplantation from haploidentical donors compared to patients receiving bone 
marrow transplantation from matched unrelated donors
Due to the fact that HLA markers are inherited, it is more likely that a 
patient will find a match within their own ethnicity. According to the Be 
The Match Registry, African American or Black patients have a 23% 
likelihood of finding a matched adult donor, Asian or Pacific Islander 
patients have a 41% likelihood of finding a matched adult donor, 
Hispanic or Latino patients have a 46% likelihood of finding a matched 
adult donor, and White patients have a 77% likelihood of finding a 
matched adult donor⁴. This clearly demonstrates the great disparity in the 
likelihood of finding a life saving donor match for bone marrow 
transplantation. Haploidentical bone marrow transplants would provide a 
treatment option for numerous patients that have children or parents 
eligible to donate their bone marrow while simultaneously expanding the 
availability of donor matches on the registry itself. The primary concern 
with the use of haploidentical donor matches in bone marrow 
transplantation has been surrounding the incidence of acute graft versus 
host disease, incidence of chronic graft versus host disease, and overall 
survival.
Study aGVHD cGVHD  OS
Sun Y et al. (2016) S NS S
Piemontese S et al. (2015) S S S
Raiola AM et al. (2014) S S S
Wang Y et al.  (2011) NS NS S
Lorentino F et al. (2018) S S S 
Piemontese S et al. (2017) S S S
Basquiera et al. (2019)  S S S
